No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
SLS241220C2000
- 0.03
- +0.01+50.00%
15min DelayClose Dec 20 16:00 ET
0.03High0.03Low
0.03Open0.02Pre Close22 Volume2.45K Open Interest2.00Strike Price66.00Turnover0.00%IV128.60%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.03Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma29.60Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Promising Phase 2 Results and Strategic Potential Drive Buy Rating for SELLAS Life Sciences' SLS009
Express News | Sellas Life Sciences Group: Study Reaches Pre-Specified Threshold of 60 Events (Deaths) Initiating Interim Analysis
Express News | Sellas Life Sciences Group: Regal Independent Data Monitoring Committee to Perform Interim Analysis in Jan 2025
Express News | Sellas Life Sciences Triggers Interim Analysis in Phase 3 Regal Trial of Gps in Acute Myeloid Leukemia
SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia
SELLAS Reports Positive Survival Data From Mid-stage Trial of Its Leukemia Treatment